Search Cancer Clinical Trials

Clinical Trials

Title	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Disease/Condition	Head and Neck Cancer
Description	The purpose of the trial is to study chemotherapy and see how well it works with or without bevacizumab in treating patients with recurrent or metastatic head and neck cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, carboplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also make tumor cells more sensitive to chemotherapy and stop the growth of head and neck cancer by blocking blood flow to the tumor. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab in treating patients with head and neck cancer.
Eligibility Criteria	To be eligible for this study, patients must meet several criteria, including but not limited to the following: * Patient must be 18 Years and older * Patient must have histologically or cytologically confirmed squamous cell carcinoma of the head and neck (SCCHN) from any primary site, including unknown primary cancers of the head and neck.
Principal Investigator	Missak Haigentz, MD
Contact Name	Yoko Eng, NP
Phone	(718) 920-2090
Contact Email	yeng@montefiore.org
Post Date	12/28/2007
Protocol Number	2008-411/East
Status	Recruiting
Current Trial Type	Interventional